DRUG · Mapped RxNorm record
Pasireotide
Normalized identity: pasireotideView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
NCT01313559
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Everolimus
Normalized identity: everolimusView linked drug · Find medicine records ·
Find other trials using this name
OTHER · Unmapped registry intervention
Laboratory biomarker analysis
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedPasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Castrate Resistant Prostate Cancerunresolved
Chemotherapy Naive Prostate Cancerunresolved
Prostate Cancerverified · MONDO: prostate cancer
Interventions
PasireotideDRUG · verified · RxNorm: pasireotide
EverolimusDRUG · verified · RxNorm: everolimus
Sponsors & collaborators
Novartis Pharmaceuticalscollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01313559 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.